Cargando…

Improving adherence with eye medication: a patient-centred approach to prescribing

Detalles Bibliográficos
Autores principales:	Wiafe, Boateng, Jha, Nisha, Wolvaardt, Elmien, Abdull, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Centre for Eye Health 2023
Materias:	Adherence & Prescribing
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236414/ https://www.ncbi.nlm.nih.gov/pubmed/37273805

Ejemplares similares

Laboratory testing and antihypertensive medication adherence following initial treatment of incident, uncomplicated hypertension: A real‐world data analysis
por: Beall, Reed F., et al.
Publicado: (2022)

Impact of medication adherence on the efficacy of Baroreflex activation therapy
por: Schäfer, Ann‐Kathrin C., et al.
Publicado: (2022)

Identification of Cardiovascular Patient Groups at Risk for Poor Medication Adherence: A Cluster Analysis
por: Sieben, Angelien, et al.
Publicado: (2021)

Comparative antiplatelet effects of chlorthalidone and hydrochlorothiazide
por: Bashir, Khalid, et al.
Publicado: (2022)

Clinical impact of medication adherence on 10‐year cardio‐cerebrovascular mortality in newly diagnosed hypertensive patients
por: Kim, Cho‐Long, et al.
Publicado: (2021)

Drug adherence and psychological factors in patients with apparently treatment‐resistant hypertension: Yes but which ones?
por: Georges, Coralie M. G., et al.
Publicado: (2022)

Early adherence to antihypertensive drugs and long‐term cardiovascular mortality in the “real world”
por: Salazar, Martin R.
Publicado: (2021)

Determination of level of self‐reported adherence of antihypertensive drug(s) and its associated factors among patient with hypertension at a tertiary care center
por: Bhusal, Laxman, et al.
Publicado: (2022)

Safety around medicines for eye care
por: Khatun, Alaya, et al.
Publicado: (2021)

Factors Associated With Nonadherence to Cardiovascular Medications: A Cross-sectional Study
por: van der Laan, Danielle M., et al.
Publicado: (2019)

Medication adherence: a review of pharmacy education, research, practice and policy in Finland
por: Bell, J. Simon, et al.
Publicado: (2010)

Medication adherence and community pharmacy: a review of education, policy and research in England
por: Clifford, Sarah, et al.
Publicado: (2010)

Failure to follow medication changes made at hospital discharge is associated with adverse events in 30 days
por: Weir, Daniala L., et al.
Publicado: (2020)

Adherence policy, education and practice – an international perspective
por: Marie-Schneider, Paule, et al.
Publicado: (2010)

Adherence: a review of education, research, practice and policy in Switzerland
por: Schneider, Marie P., et al.
Publicado: (2009)

Adherence: a review of education, research, practice and policy in Australia
por: Aslani, Parisa, et al.
Publicado: (2009)

Adherence: a review of education, research, practice and policy in Spain
por: Fikri-Benbrahim, Narjis, et al.
Publicado: (2009)

Adherence to treatment: practice, education and research in Danish community pharmacy
por: Haugbølle, Lotte S., et al.
Publicado: (2009)

Adherence to treatment: what is done in Sweden? Practice, education and research
por: Södergård., Björn
Publicado: (2008)

Adherence: a review of education, research, practice, and policy in the United States
por: Rickles, Nathaniel M., et al.
Publicado: (2010)

Putting patients first: how to carry out a patient-centred eye examination
por: du Toit, Renee, et al.
Publicado: (2019)

Improving antibiotic prescribing for children in the resource-poor setting
por: Le Doare, Kirsty, et al.
Publicado: (2015)

Community Eye Health Journal – promoting improvement in eye health for over 20 years
por: Ellison, Elmien Wolvaardt
Publicado: (2012)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020)

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
por: Douglas, Melanie
Publicado: (2020)

Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
por: Hua, Gwen, et al.
Publicado: (2023)

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma
por: Ketchum, Emily Behren, et al.
Publicado: (2022)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

A Review of PI3K Inhibitors in B-Cell Malignancies
por: Cannon, Laura, et al.
Publicado: (2019)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
por: King, Amber C., et al.
Publicado: (2019)

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
por: Fleming, Patrick J., et al.
Publicado: (2021)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lpqq8rnbkil8q8shtuej6ocsph